Immunotherapy, especially immune checkpoint inhibitors (ICIs) therapy (e.g., anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) therapy) and adoptive cell therapy (ACT), has made significant clinical progress in cancer treatment. This evidence concerns the gene PDCD1 and cancer.